Muscle Invasive Bladder Cancer Market Size & Share, by Type (Surgical Treatment, Non-Surgical Treatment), End User (Hospitals, Patients, Pharmaceuticals) - Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5401
  • Published Date: Nov 27, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Muscle Invasive Bladder Cancer Market size is poised to reach USD 48 billion by the end of 2036, growing at a CAGR of 10% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of muscle invasive bladder cancer was over USD 21 billion. The rising personalized medicine and biomarker development is one of the main growth drivers expanding the market. A transformative and yet underutilized growth driver in the market is the integration of personalized medicine and the development of specific biomarkers. According to a study, the use of personalized medicine guided by biomarkers has shown a 30% improvement in progression-free survival in patients who received personalized treatments compared to those who underwent conventional treatments.

The future outlook for the MIBC market is positive, with the market expected to continue to grow in the coming years. This growth will be driven by the rising incidence of MIBC, the increasing prevalence of risk factors, and the development of new and more effective treatments. Muscle-invasive bladder cancer (MIBC) is a type of bladder cancer that has invaded the muscularis propria, the middle layer of the bladder wall. MIBC is more aggressive than non-muscle-invasive bladder cancer (NMIBC) and is more likely to spread to other parts of the body.

Get more information on this report: Request Free Sample PDF

Muscle Invasive Bladder Cancer Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising incidence of MIBC - The incidence of MIBC is increasing globally, due in part to the aging population and the increasing prevalence of risk factors such as smoking. According to the American Cancer Society, bladder cancer is the sixth most common cancer in the United States among both men and women. In 2022, it is estimated that there will be 76,960 new cases of bladder cancer diagnosed in the United States. Of these, approximately 50,000 will be NMIBC and 27,000 will be MIBC.
  • Advances in Medical Technology - Continuous advancements in diagnostic tools, imaging techniques, and treatment modalities have enhanced the diagnosis and management of MIBC. These innovations have improved patient outcomes and spurred muscle invasive bladder cancer market growth. The adoption of minimally invasive surgical techniques, such as robot-assisted surgery, has shown promising outcomes in MIBC treatment, leading to increased demand. Medical imaging and diagnostic tools have become increasingly precise and less invasive. Innovations in radiology and urology have significantly improved the early detection of MIBC.
  • Development of Targeted Therapies - The emergence of targeted therapies and immunotherapies for MIBC has transformed the treatment landscape. These therapies offer more effective and less toxic options, leading to market growth. Immune checkpoint inhibitors, such as pembrolizumab, have demonstrated significant efficacy in MIBC treatment, leading to improved survival rates. Targeted therapies are designed to specifically target the molecular and genetic characteristics of cancer cells.


  • Late-stage Diagnosis - Many cases of MIBC are diagnosed at an advanced stage due to non-specific symptoms or a lack of routine screening. Late-stage diagnosis often results in a poorer prognosis and limited treatment options. MIBC often presents with non-specific symptoms that can be mistaken for other, less serious conditions. The most common symptom is hematuria, or blood in the urine. While hematuria is a clear warning sign of bladder cancer, it can also be caused by urinary tract infections, kidney stones, or other benign conditions.
  • Limited Early Detection Methods
  • MIBC is characterized by its aggressive nature with side effects

Muscle Invasive Bladder Cancer Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 21 Billion

Forecast Year Market Size (2036)

~ USD 48 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Muscle Invasive Bladder Cancer Segmentation

Type (Surgical Treatment, Non-Surgical Treatment)

The surgical treatment segment in the muscle invasive bladder cancer market is estimated to gain the largest revenue share of 61% in the year 2036. Compelling growth driver for surgical treatments in the MIBC market is the potential for cure. Radical cystectomy, in particular, offers a chance for certain patients to achieve long-term disease-free survival. While not all MIBC cases are curable, a subset of patients benefits from this aggressive surgical approach. A study published in "The Lancet" Oncology revealed that a subset of MIBC patients who underwent radical cystectomy experienced long-term disease-free survival, suggesting the potential for cure. Surgical interventions have the potential to eliminate cancerous tissue entirely, especially in cases where the cancer is confined to the bladder. Patients who achieve complete remission after surgery may experience long-term disease control and a potential cure.

End User (Hospitals, Patients, Pharmaceuticals)

Muscle invasive bladder cancer market from the hospitals segment is expected to garner a significant share in the year 2036. One significant growth driver for the hospitals segment in the MIBC market is the establishment of multidisciplinary care teams. MIBC is a complex disease that often requires a multifaceted approach to diagnosis and treatment. Multidisciplinary care teams consist of various specialists, including urologists, medical oncologists, radiation oncologists, pathologists, radiologists, and nurses, who collaborate to provide comprehensive care for MIBC patients. A study published in the "Journal of Clinical Oncology" found that multidisciplinary care teams, involving urologists, medical oncologists, and radiation oncologists, are associated with improved survival outcomes in MIBC patients.

Our in-depth analysis of the global market includes the following segments:


  • Surgical Treatment
  • Non-Surgical Treatment



           End User

  • Hospitals
  • Patients
  • Pharmaceuticals

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Muscle Invasive Bladder Cancer Industry - Regional Synopsis

APAC Market Forecast

The muscle invasive bladder cancer market in the Asia Pacific region is projected to hold the largest revenue share of 40% by the end of 2036. Advances in medical technology are a significant growth driver in the MIBC market in the Asia Pacific region. The region has witnessed the adoption of state-of-the-art medical technologies, including advanced imaging techniques, diagnostic tools, and treatment modalities. The Asia Pacific region has embraced technological advancements in the field of medical imaging, including the use of positron emission tomography-computed tomography (PET-CT) for precise staging of MIBC. In particular, the use of positron emission tomography-computed tomography (PET-CT) has gained prominence in the precise staging of MIBC. This imaging modality allows for the comprehensive assessment of the extent of the disease, facilitating treatment planning and decision-making.

North American Market Statistics

The muscle invasive bladder cancer market in the North America region is projected to hold the second largest share during the forecast period. One of the prominent growth drivers in the MIBC market in North America is the aging population. The United States and Canada, in particular, are witnessing a demographic shift with a growing elderly population. In the United States, the aging population is growing rapidly, with the number of individuals aged 65 and older projected to reach 88 million by 2050. Muscle-invasive bladder cancer is more common in older individuals. The aging process can lead to cellular changes in the bladder, making it more susceptible to carcinogenic factors. Therefore, the rising elderly population directly contributes to the increased incidence of MIBC in North America.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Muscle Invasive Bladder Cancer Landscape

    • Bristol-Myers Squibb Company
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • AstraZeneca PLC
    • Johnson & Johnson
    • Novartis International AG
    • Sanofi S.A.
    • Pfizer Inc.
    • Eli Lilly and Company
    • Astellas Pharma Inc.

In the News

  • Bristol Myers Squibb acquired Turning Point Therapeutics, a leading precision oncology company, for USD 76.00 per share. The acquisition expanded Bristol Myers Squibb's portfolio of cancer drugs and pipeline.
  • Bristol Myers Squibb announced a definitive agreement to acquire Mirati Therapeutics, Inc. for USD 58.00 per share. The acquisition expanded Bristol Myers Squibb's portfolio of cancer drugs and pipeline, particularly in the area of KRAS-mutated cancer.

Author Credits:  Radhika Pawar

  • Report ID: 5401
  • Published Date: Nov 27, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for healthcare sector is the major factor driving the market growth.

The market size of muscle invasive bladder cancer is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2024-2036.

The major players in the market Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AstraZeneca PLC, Johnson & Johnson, Novartis International AG, and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Muscle Invasive Bladder Cancer Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying